Jun 28, 2023Long-term Clinical Study Demonstrates Disease-Modifying Effects of ANAVEX®2-73 for Rett Syndrome
Jun 12, 2023Anavex Life Sciences Reports Publication in Medical Journal for Continued Commitment to Improve RSBQ
Jun 6, 2023Completion of ANAVEX®2-73 (blarcamesine) EXCELLENCE Phase 2/3 Rett Syndrome Clinical Trial
May 2, 2023Anavex Life Sciences to Announce Fiscal 2023 Second Quarter Financial Resultson Tuesday May 9, 2023
Mar 30, 2023ANAVEX®2-73 (Blarcamesine) Shows Clinical Benefit in Long-Term 48Week Phase 2 Extension Study in PDD
Mar 9, 2023Anavex Life Sciences Appoints Former FDA Lead Neurology Statistician as VP Head of Biostatistics
Feb 2, 2023Anavex Life Sciences Announces Exceeding of Enrollment Target for ANAVEX®2-73 (blarcamesine)
Jan 31, 2023Anavex Life Sciences to Announce Fiscal 2023 First Quarter Financial Results on February 7, 2023
Dec 14, 2022Anavex Strengthens Scientific Advisory Board with Investigator from Phase 2b/3 Alzheimer’s Trial
Dec 2, 2022Anavex Life Sciences to Announce Management Webcast and Conference Call on Monday December 5, 2022
Nov 28, 2022Anavex Life Sciences Reports Fiscal 2022 Year End Financial Results and Provides Business Update
Nov 8, 2022Anavex Life Sciences to Present at the Guggenheim 4th Annual Immunology and Neurology Conference
Sep 21, 2022Anavex Life Sciences new U.S. Patent ANAVEX®2-73 (blarcamesine) for Neurodevelopmental Disorders
Aug 9, 2022Anavex Life Sciences Provides Business Update & Reports Fiscal 2022 Third Quarter Financial Results
Aug 3, 2022Anavex Life Sciences to Announce Fiscal 2022 Third Quarter Financial Results on Tuesday, Aug. 9 2022